• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ARCA biopharma Inc.

    9/11/23 4:01:28 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ABIO alert in real time by email
    SC 13G 1 d463318dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.             )*

     

     

    ARCA biopharma, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class Securities)

    00211Y506

    (CUSIP Number)

    August 30, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     


    Page 2 of 9 Pages

    CUSIP No. 00211Y506

     

     

      1    

      NAME OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Western Standard, LLC

      26-2921385

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      944,234

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      944,234

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      944,234

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IA

     


    Page 3 of 9 Pages

    CUSIP No. 00211Y506

     

     

      1    

      NAME OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Eric D. Andersen

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      944,234

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      944,234

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      944,234

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      6.6%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN, HC

     


    Page 4 of 9 Pages

    CUSIP No. 00211Y506

     

     

      1    

      NAME OF REPORTING PERSONS.

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

     

      Western Standard Partners, L.P.

      26-2921468

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (A)  ☐        (B)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

      SOLE VOTING POWER

     

      742,410

       6   

      SHARED VOTING POWER

     

      0

       7   

      SOLE DISPOSITIVE POWER

     

      742,410

       8   

      SHARED DISPOSITIVE POWER

     

      0

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      742,410

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.2%

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     


    Page 5 of 9 Pages

     

    Item 1.

     

      (a)

    Name of Issuer

    ARCA biopharma, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    10170 Church Ranch Way, Suite 100, Westminster, CO, 80021

    Item 2.

     

      (a)

    Name of Person Filing

    This Schedule 13G is being filed on behalf of Western Standard, LLC, Eric D. Andersen, and Western Standard Partners, L.P. (each, a “Reporting Person”).

     

      (b)

    Address of Principal Business office or, if None, Residence

    For each Reporting Person,

    5757 Wilshire Blvd, Suite 636, Los Angeles, California 90036

     

      (c)

    Citizenship

    Western Standard, LLC is a California limited liability company

    Western Standard Partners, L.P. is a Delaware limited partnership

    Mr. Andersen is a United States citizen

     

      (d)

    Title of Class of Securities

    Common Stock, par value $0.001 per share

     

      (e)

    CUSIP Number

    00211Y506

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).
    (e)    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).


    Page 6 of 9 Pages

     

    (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(ii)(F).
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)    ☐    Group in accordance with § 240.13d-1(b)(ii)(J).

     

    Item 4.

    Ownership

    For each of Western Standard, LLC and Eric A. Andersen:

    (a) Amount beneficially owned: 944,234 (the “Shares”) **

    (b) Percent of class: 6.6% *

    (c) Number of shares to which the Reporting Person has:

    (i) Sole power to vote or to direct the vote: 944,234

    (ii) Shared power to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 944,234

    (iv) Shared power to dispose or to direct the disposition of: 0

    For each of Western Standard Partners, L.P.:

    (a) Amount beneficially owned: 742,410

    (b) Percent of class: 5.2%*

    (c) Number of shares to which the Reporting Person has:

    (i) Sole power to vote or to direct the vote: 742,410

    (ii) Shared power to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 742,410

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    *

    Percentage calculated based on 14,410,143 shares of Common Stock outstanding as of July 20, 2023, as reported in the issuer’s most recent Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission on July 21, 2023.


    Page 7 of 9 Pages

     

    **

    Western Standard, LLC, in its capacity as investment adviser to Western Standard Partners, L.P. and another private investment fund (the “Funds”), may be deemed to beneficial own the Shares owned by the Funds due to its power to direct the disposition and voting of the Shares owned by the Funds. Eric D. Andersen is the Managing Member of Western Standard, LLC and may also be deemed to beneficially own the Shares owned by the Funds. Pursuant to Rule 13d-4, each of Western Standard LLC and Eric D. Andersen disclaims beneficial ownership of the securities owned by the Funds, except to the extent of its or his pecuniary interest in the Shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Item 10.

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    Page 8 of 9 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: September 11, 2023

     

    Western Standard Partners, L.P.
    By: Western Standard, LLC, its General Partner
    By:  

    /s/ Eric D. Andersen

      Eric D. Andersen, Managing Member
    Western Standard, LLC
    By:  

    /s/ Eric D. Andersen

      Eric D. Andersen, Managing Member
     

    /s/ Eric D. Andersen

      Eric D. Andersen


    Page 9 of 9 Pages

     

    Exhibit A

    Joint Filing Agreement Pursuant to Rule 13d-1

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of ARCA biopharma Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

    The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

    It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties hereto.

    Date: September 11, 2023

     

    Western Standard Partners, L.P.
    By: Western Standard, LLC, its General Partner
    By:  

    /s/ Eric D. Andersen

      Eric D. Andersen, Managing Member
    Western Standard, LLC
    By:  

    /s/ Eric D. Andersen

      Eric D. Andersen, Managing Member
     

    /s/ Eric D. Andersen

      Eric D. Andersen
    Get the next $ABIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc was granted 275,000 shares (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/13/24 4:55:08 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Fairmount Funds Management Llc claimed ownership of 2,936,922 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/6/24 5:07:49 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Turtle Cameron claimed ownership of 85,233 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/6/24 5:07:01 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    SEC Filings

    View All

    ARCA biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/13/24 4:02:39 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change

    8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/5/24 5:18:25 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 425 filed by ARCA biopharma Inc.

    425 - ARCA biopharma, Inc. (0000907654) (Subject)

    8/26/24 7:53:54 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

    WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with

    8/29/24 4:50:15 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special

    8/26/24 7:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of

    8/23/24 4:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Financials

    Live finance-specific insights

    View All

    ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

    WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with

    8/29/24 4:50:15 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special

    8/26/24 7:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

    WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of

    8/23/24 4:30:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/13/24 4:57:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D filed by ARCA biopharma Inc.

    SC 13D - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/6/24 5:08:49 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by ARCA biopharma Inc.

    SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)

    4/29/24 7:28:44 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    Leadership Updates

    Live Leadership Updates

    View All

    ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna

    4/25/24 4:15:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care